Jazz Pharmaceuticals plc
zanidatamab
1L GEA
Countdown
542days
Phase 1 readout · ~ Dec 31, 2027 estimated
What's at stake
Phase 1 trial results for zanidatamab in 1L GEA are due ~ Dec 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“EmpowHER-BC-303 trial top-line in Rare Disease to drive Full-year commercial sales1 in readout late 2027 / early 2028”